UK biopharmaceuticals research projects win £4m of funding

Aim to strengthen UK’s position in the sector

A package of projects, studentships and training announced today (13 June) aims to develop research to underpin the production and processing of new types of medicines based on biological molecules in the UK.

These projects will provide the foundations for the UK pharmaceutical sector to strengthen its position in the biopharmaceutical sector to the benefit of society and the economy.

The Bioprocessing Research Industry Club (BRIC), a Biotechnology and Biological Sciences Research Council (BBSRC)-led public-private partnership with the Engineering and Physical Sciences Research Council (EPSRC) and a consortium of 16 industrial partners, including companies such as Pfizer, GlaxoSmithKline, Lonza and Biodesign, is providing £4m to fund the projects.

This money will go to six research projects, eight PhD studentships and a Skills Development School for early stage researchers.

The projects will address current challenges in bioprocessing, while the PhD studentships and Skills Development School will ensure that the next generation of researchers have the technical knowledge and personal skills to secure future UK success in producing biopharmaceuticals.

Each PhD student will spend six months or a year on placement with a partner company where they will develop an understanding of the challenges involved in producing biological medicines on a commercial scale.

Biopharmaceuticals such as vaccines, monoclonal antibodies, hormones and peptide therapeutics, make up over a third of the medicines currently under development and the number of licensed biological medicines is expected to grow by 20% a year.

You may also like

Research & Development

Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases

The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Manufacturing

Symbiosis expands sterile manufacturing capacity with fill/finish line qualification

Symbiosis has maintained a track record of successful GMP inspections with both the FDA and MHRA since it was founded
Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Finance

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
Subscribe now